Please login to the form below
ENSEMBLE
This page shows the latest ENSEMBLE news and features for those working in and with pharma, biotech and healthcare.
J&J’s COVID-19 vaccine shows ‘strong’ activity against Delta variant
A pre-print paper, submitted to bioRxiv yesterday, includes analysis from blood samples taken from a group of participants in J&J’s phase 3 ENSEMBLE COVID-19 vaccine study.
Latest news
-
Roche’s Ocrevus shows significant benefit in early-stage MS patients
The data, presented virtually at the American Academy of Neurology (AAN) annual meeting, comes from the open label phase IIIb ENSEMBLE and a post-hoc analysis of the phase III ORATORIO ... studies. In the ENSEMBLE study, 85% of recently diagnosed RRMS
-
WHO backs emergency use of J&J’s one-dose COVID-19 vaccine
In the phase 3 ENSEMBLE trial, J&J’s vaccine was 66.1% effective overall in preventing moderate-to-severe COVID-19, 28 days after vaccination.
-
J&J’s one-dose COVID-19 vaccine granted EU authorisation
J&J submitted its vaccine for a CMA in the EU in February, basing the submission on top-line efficacy and safety data from the phase 3 ENSEMBLE trial. ... The ENSEMBLE study was conducted in eight countries across three continents, with 44% of
-
Merck & Co to help produce J&J’s COVID-19 vaccine in the US
J&J’s phase 3 ENSEMBLE trial found that the vaccine was 66% effective overall in preventing moderate-to-severe COVID-19, 28 days after vaccination.
-
J&J’s one-dose COVID-19 vaccine granted emergency use approval by FDA
trial. The EUA was supported by data from the phase 3 ENSEMBLE trial, within which J&J’s vaccine demonstrated 85% efficacy against severe COVID-19 across all regions studied.
Roche’s Ocrevus shows significant benefit in early-stage MS patients
WHO backs emergency use of J&J’s one-dose COVID-19 vaccine
J&J’s one-dose COVID-19 vaccine granted EU authorisation
Merck & Co to help produce J&J’s COVID-19 vaccine in the US
More from news
Approximately 1 fully matching, plus 22 partially matching documents found.
Latest Intelligence
-
Stepping out
The ‘one-size-fits-all’ approach will not change behaviours.”. An ensemble performance. Naturally, patients are the focal point of behaviour change programmes.
-
Integrated thinking - it’s both art and science
While these guys may not sound as good together as the ensemble musical cast of Station to Station or “Heroes”, there's little doubt this approach represents a refreshing challenge to
-
Pharma deals during November 2012
230. Cipla Medpro / Cipla. Acquisition. Generics. 215. Ensemble Therapeutics / Boehringer Ingelheim.
Stepping out
Integrated thinking - it’s both art and science
Pharma deals during November 2012
More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
- Project Director, Healthcare Marketing Agency patient focus Lond...
-
Highly competitive salary
- Account Manager - Healthcare Consultancy
-
Salary depending on experience
-
Digital account director
-
Competitive
- Senior Consultant, Pricing & Market Access Consultancy, circ...
-
circa £100K package
- Principal/ Senior/ Medical Writer – Global Med Ed and Comms Agen...
-
Highly competitive salary
- Digital Project Director, Healthcare Marketing Agency patient fo...
-
Highly competitive salary
-
Events Executive
-
Depending on Experience
- One dose of AZ’s COVID-19 vaccine ‘highly effective’ against severe disease from variants
- Mixing AZ and Pfizer COVID-19 vaccines increases antibody levels
- AZ publishes new real-world safety data for COVID-19 vaccine Vaxzevria
- CHMP rejects Kyowa Kirin’s Parkinson’s disease drug
- The Chronicles of Pharma: a creative review of pharma’s journey to omnichannel
- Google’s DeepMind opens ‘breakthrough’ protein database to the world
- Merck & Co’s sales bounce back in ‘ongoing recovery from COVID-19’
- Lilly and Kumquat Biosciences link up in $2bn-plus immuno-oncology deal
- Michael J. Fox Foundation and IBM reveal new AI model for Parkinson’s disease
- BMS’ Q2 results beat expectations with strong performance across core therapy areas
- Amanda Pritchard becomes NHS England’s first female chief executive
- Understanding the ‘real world’ starts and ends with the patient
- Onyx Health Launch Creative Studio After Record Year
- BioNTech plans acquisition of Kite’s TCR cell therapy R&D platform
- One dose of AZ’s COVID-19 vaccine ‘highly effective’ against severe disease from variants
- The Chronicles of Pharma: a creative review of pharma’s journey to omnichannel
- Tonix Pharmaceuticals to develop TNX-102 for long COVID syndrome
- Migraine-friendly colours for the home
PMHub
Aptus Health
Aptus Health is dedicated to advancing health engagement. The company offers end-to-end digital health engagement solutions spanning all areas of...
Latest intelligence
- Top 10 ways to leverage the Impetus InSite Platform® to (virtually) launch your brand
- The Impetus InSite Platform® can be used to facilitate virtual and hybrid engagement at all stages of the product lifecycle. Here, we share 10 of the most popular ways to...
- Employee wellbeing in creative agencies: three tips to get you started
- Paul Hutchings, founder of fox&cat, and new friend, Welfy, a workplace wellbeing training firm, discuss the importance of collaboration...
- Managing unhelpful pressure in your creative agency: the human approach
- Paul Hutchings, founder of fox&cat, answers the questions: what does it mean to be human in 2021? Are we putting ourselves under too much pressure?...
